{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Nkumama IN"],"funding":["EPA","National Institute for Health Research (NIHR)","Wellcome Trust"],"pagination":["1215-1224.e6"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7616646"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["57(6)"],"pubmed_abstract":["Malaria is a life-threatening disease of global health importance, particularly in sub-Saharan Africa. The growth inhibition assay (GIA) is routinely used to evaluate, prioritize, and quantify the efficacy of malaria blood-stage vaccine candidates but does not reliably predict either naturally acquired or vaccine-induced protection. Controlled human malaria challenge studies in semi-immune volunteers provide an unparalleled opportunity to robustly identify mechanistic correlates of protection. We leveraged this platform to undertake a head-to-head comparison of seven functional antibody assays that are relevant to immunity against the erythrocytic merozoite stage of Plasmodium falciparum. Fc-mediated effector functions were strongly associated with protection from clinical symptoms of malaria and exponential parasite multiplication, while the gold standard GIA was not. The breadth of Fc-mediated effector function discriminated clinical immunity following the challenge. These findings present a shift in the understanding of the mechanisms that underpin immunity to malaria and have important implications for vaccine development."],"journal":["Immunity"],"pubmed_title":["Breadth of Fc-mediated effector function correlates with clinical immunity following human malaria challenge."],"pmcid":["PMC7616646"],"funding_grant_id":["107499/Z/15/Z","226669/Z/22/Z","EP-C-15-003","107499","16/136/33","107769/Z/10/Z"],"pubmed_authors":["Mwai K","CHMI-SIKA study team","Frank R","Rosenkranz M","Musasia F","Tuju J","Osier FHA","Furle K","Ogwang R","Kapulu MC","Odera D","Nyamako L","Nkumama IN","Murungi L","Njuguna P","Kimathi R","Hamaluba M"],"additional_accession":[]},"is_claimable":false,"name":"Breadth of Fc-mediated effector function correlates with clinical immunity following human malaria challenge.","description":"Malaria is a life-threatening disease of global health importance, particularly in sub-Saharan Africa. The growth inhibition assay (GIA) is routinely used to evaluate, prioritize, and quantify the efficacy of malaria blood-stage vaccine candidates but does not reliably predict either naturally acquired or vaccine-induced protection. Controlled human malaria challenge studies in semi-immune volunteers provide an unparalleled opportunity to robustly identify mechanistic correlates of protection. We leveraged this platform to undertake a head-to-head comparison of seven functional antibody assays that are relevant to immunity against the erythrocytic merozoite stage of Plasmodium falciparum. Fc-mediated effector functions were strongly associated with protection from clinical symptoms of malaria and exponential parasite multiplication, while the gold standard GIA was not. The breadth of Fc-mediated effector function discriminated clinical immunity following the challenge. These findings present a shift in the understanding of the mechanisms that underpin immunity to malaria and have important implications for vaccine development.","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jun","modification":"2026-06-03T05:27:32.353Z","creation":"2025-04-04T08:23:14.308Z"},"accession":"S-EPMC7616646","cross_references":{"pubmed":["38788711"],"doi":["10.1016/j.immuni.2024.05.001"]}}